Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.33 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520964 | 0.90 | HSD11B1 (0.38) | CTSDBACE1HSD11B1HSD11B2 | |
| SCHEMBL31274980 | 0.89 | CHRNA1 (0.32) | CTSDBACE1 | |
| SCHEMBL29605058 | 0.88 | HSD11B1 (0.34) | CTSDBACE1HSD11B1 | |
| SCHEMBL29614312 | 0.87 | HSD11B1 (0.41) | CTSDBACE1HSD11B1HSD11B2 | |
| SCHEMBL30728152 | 0.87 | HSD11B1 (0.44) | CTSDBACE1HSD11B1HSD11B2 | |
| SCHEMBL25411577 | 0.87 | HSD11B1 (0.44) | CTSDBACE1HSD11B1HSD11B2 | |
| SCHEMBL29606090 | 0.85 | BACE1 (0.32) | CTSDBACE1 | |
| SCHEMBL30374023 | 0.85 | HSD11B1 (0.32) | CTSDBACE1HSD11B1 | |
| SCHEMBL25178762 | 0.85 | HSD11B1 (0.32) | CTSDBACE1HSD11B1 | |
| SCHEMBL22832590 | 0.84 | CHRNA1 (0.34) | CTSDBACE1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4653436-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| CN-114364670-B | Substituted benzyl-triazole compound for Cbl-b inhibition and further application thereof | 纽力克斯治疗公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2024153240-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 珠海宇繁生物科技有限责任公司 | 2024-07-25 | — | — | WO | disclosed |
| WO-2024105563-A1 | SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES | PFIZER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023151642-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151641-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023151640-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE , LTD. (KY) | 2023-08-17 | — | — | WO | disclosed |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-11401267-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | NURIX THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3990117-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | Nurix Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114364670-A | Substituted benzyl-triazoles for Cbl-b inhibition and further uses thereof | 纽力克斯治疗公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2020264398-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401267-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | CBL, CBLB, CBLC | CTSD 1404/4885BACE1 1932/4885HSD11B1 3566/4885 |
| US-20230150991-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CTSD 1404/4885BACE1 1932/4885HSD11B1 3566/4885 |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | CTSD 4391/4885BACE1 3677/4885HSD11B1 962/4885 |
| US-12234230-B2 | Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof | CBL, CBLB, CBLC | CTSD 1404/4885BACE1 1932/4885HSD11B1 3566/4885 |
| US-20250136590-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CTSD 1404/4885BACE1 1932/4885HSD11B1 3566/4885 |
| US-20210053961-A1 | SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOF | CBL, CBLB, CBLC | CTSD 1404/4885BACE1 1932/4885HSD11B1 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.